A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects

Essentials DS‐1040 inhibits the activated form of thrombin‐activatable fibrinolysis inhibitor (TAFIa). Infusion of DS‐1040 was safe and well tolerated in healthy young and elderly subjects. DS‐1040 substantially decreased TAFIa activity but had no impact on bleeding time. DS‐1040 may provide an opti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2017-05, Vol.15 (5), p.961-971
Hauptverfasser:	Zhou, J., Kochan, J., Yin, O., Warren, V., Zamora, C., Atiee, G., Pav, J., Orihashi, Y., Vashi, V., Dishy, V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Age Factors Aged Bleeding Blood Coagulation Tests Carboxypeptidase B2 - antagonists & inhibitors Carboxypeptidase B2 - metabolism Coagulation Dose-Response Relationship, Drug Female Fibrinolysis Fibrinolysis - drug effects Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - adverse effects Fibrinolytic Agents - pharmacokinetics Geriatrics Healthy Volunteers Hemorrhage - chemically induced Humans Infusions, Intravenous Intravenous administration Ischemia Kidneys Lysis Male Middle Aged Molecular weight Pharmacodynamics Pharmacokinetics Platelet aggregation Protease Inhibitors - administration & dosage Protease Inhibitors - adverse effects Protease Inhibitors - pharmacokinetics Risk Factors Stroke Thrombin thrombin‐activatable fibrinolysis inhibitor Thromboembolism Thrombolysis thrombosis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!